155 related articles for article (PubMed ID: 3435922)
1. Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models.
Ricci F; De Filippi R; Riccardi C; Romani L; Giuliani A
Chemioterapia; 1987 Dec; 6(6):403-9. PubMed ID: 3435922
[TBL] [Abstract][Full Text] [Related]
2. [The use of BCG as immunoadjuvant in combination with antitumor drugs in a virus induced leukemia. II].
Perito S; Cenci E; Sbaraglia G; Vecchiarelli A
Boll Soc Ital Biol Sper; 1980 Dec; 56(23):2511-7. PubMed ID: 7470294
[TBL] [Abstract][Full Text] [Related]
3. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
5. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
6. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA; Greenberg PD; Fefer A
Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
[TBL] [Abstract][Full Text] [Related]
7. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
Kende M; Keys LD; Gaston M; Goldin A
Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
[TBL] [Abstract][Full Text] [Related]
9. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
12. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
13. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
[TBL] [Abstract][Full Text] [Related]
14. Role of vincristine in immunochemotherapy of leukemia in mouse or human models.
Prete SP; De Filippi R; Silvi E; Bartocci A; Giuliani A
Immunopharmacol Immunotoxicol; 1990; 12(1):135-57. PubMed ID: 2351791
[TBL] [Abstract][Full Text] [Related]
15. [Use of BCG as an immunoadjuvant in combination with antitumor agents in virus-induced leukemia].
Sbaraglia G; Cenci E; Vecchiarelli A; Perito S
Boll Soc Ital Biol Sper; 1980 Oct; 56(19):1969-75. PubMed ID: 7459108
[TBL] [Abstract][Full Text] [Related]
16. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
Kataoka T; Akahori Y; Sakurai Y
Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-increased antineoplastic effects of antibody-toxin conjugates.
Sironi M; Canegrati MA; Romano M; Vecchi A; Spreafico F
Cancer Treat Rep; 1984 Apr; 68(4):643-5. PubMed ID: 6713420
[TBL] [Abstract][Full Text] [Related]
18. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).
Loewenthal E; Weiss L; Samuel S; Or R; Slavin S
Bone Marrow Transplant; 1993 Aug; 12(2):109-13. PubMed ID: 8401354
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
